mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats.
Addiction to methamphetamine is a significant public health problem, and there are currently no pharmacological agents that are approved for the treatment of addiction to this powerful psychostimulant. Chronic methamphetamine use leads to cognitive dysfunction as well as numerous psychiatric, neurological, and cardiovascular complications. There is a growing body of literature implicating an important role for glutamate neurotransmission in psychostimulant addiction. In the present study, we examined the effects of the selective type 5 metabotropic glutamate receptor (mGluR5) antagonist 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) on intravenous self-administration of methamphetamine and reinstatement of methamphetamine-seeking behavior. Adult male Sprague-Dawley rats were trained to respond for intravenous methamphetamine (0.1 or 0.2 mg/kg per infusion) or food pellets and were subsequently administered vehicle or MTEP (0.3-3 mg/kg) before drug or food self-administration on a fixed-ratio 1 (FR1) schedule of reinforcement or a progressive ratio (PR) schedule of reinforcement. We also examined the effects of vehicle or MTEP (0.3-3 mg/kg) on cue- and drug-induced reinstatement of methamphetamine-seeking behavior as well as cue-induced reinstatement of food-seeking behavior. Our results show that MTEP dose dependently reduced the reinforcing effects of methamphetamine under FR1 and PR schedules of reinforcement without altering overall responding for food. MTEP also dose dependently prevented cue- and drug-induced reinstatement of methamphetamine-seeking behavior, but did not alter cue-induced reinstatement of food-seeking behavior. Together, these results indicate that mGluR5 receptors mediate methamphetamine reinforcement and methamphetamine-seeking behavior, and that pharmacological inhibitors of mGluR5 receptor function may represent a novel class of potential therapeutic agents for the treatment of methamphetamine addiction.
Gass
Justin T
JT
Department of Psychiatry and Behavioral Sciences, Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC 29425, USA.
Osborne
Megan P H
MP
Watson
Noreen L
NL
Brown
Jordan L
JL
Olive
M Foster
MF
D019969:Amphetamine-Related Disorders / Q000188:drug therapy*; D000704:Analysis of Variance; D000818:Animals; D001070:Appetitive Behavior / Q000187:drug effects; D016739:Behavior, Addictive / Q000188:drug therapy*; D001522:Behavior, Animal / Q000187:drug effects; D003463:Cues; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005502:Food; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D012055:Reinforcement Schedule; D012646:Self Administration; D013844:Thiazoles / Q000627:therapeutic use*
C472365:3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine; D018691:Excitatory Amino Acid Antagonists; D011725:Pyridines; D018094:Receptors, Metabotropic Glutamate; D013844:Thiazoles; D008694:Methamphetamine
J Neurosci. 2003 Apr 15;23(8):3531-7
12716962
J Pharmacol Exp Ther. 2005 Apr;313(1):395-402
15590770
Behav Brain Res. 2006 Oct 2;173(1):148-52
16834996
J Pharmacol Exp Ther. 2005 Mar;312(3):1232-40
15550570
Neuropsychopharmacology. 2004 Jul;29(7):1259-69
15010696
Psychopharmacology (Berl). 2007 Jul;192(4):571-80
17347848
CNS Drug Rev. 2006 Summer;12(2):149-66
16958988
Brain Res. 2007 Mar 2;1135(1):129-35
17198685
Ann N Y Acad Sci. 2008 Oct;1139:206-11
18991866
J Med Chem. 2003 Jan 16;46(2):204-6
12519057
Neuropsychopharmacology. 2006 Apr;31(4):778-86
16123768
J Psychiatry Neurosci. 2006 Sep;31(5):301-13
16951733
Psychopharmacology (Berl). 2003 Feb;165(4):359-69
12491026
Neuroscience. 1999;93(4):1359-67
10501460
Brain Res. 1992 Oct 30;594(2):327-30
1360323
Brain Res. 1994 Apr 18;643(1-2):276-81
7518327
Psychopharmacology (Berl). 2003 May;167(3):257-64
12682710
Pharmacol Biochem Behav. 1976 Jan;4(1):73-83
4819
Drug Alcohol Rev. 2008 May;27(3):253-62
18368606
Brain Res Bull. 1997;44(3):221-7
9323434
Cochrane Database Syst Rev. 2001;(4):CD003021
11687170
Addiction. 2007 Apr;102 Suppl 1:96-106
17493058
J Med Chem. 2006 Feb 9;49(3):1080-100
16451073
Alcohol Clin Exp Res. 2008 Feb;32(2):209-21
18162077
Br J Pharmacol. 2004 Jul;142(6):991-1001
15210575
J Neural Transm Gen Sect. 1993;91(2-3):241-54
8099799
Ann N Y Acad Sci. 2003 Nov;1003:415-8
14684476
Curr Psychiatry Rep. 2006 Oct;8(5):345-54
16968614
Neuropharmacology. 2007 Feb;52(2):263-9
16963088
Am Fam Physician. 2007 Oct 15;76(8):1169-74
17990840
Neuroscience. 2001;106(3):579-87
11591458
Eur J Pharmacol. 2005 Dec 5;526(1-3):65-76
16321382
Drug Alcohol Depend. 2006 Nov 8;85(2):142-56
16697125
Neuropharmacology. 1999 Oct;38(10):1569-76
10530818
Mayo Clin Proc. 2006 Jan;81(1):77-84
16438482
J Neurosci. 2007 Aug 22;27(34):9077-85
17715344
Synapse. 1994 Jul;17(3):203-9
7974204
Neuropharmacology. 2005;49 Suppl 1:167-78
16023685
Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):653-71
2851859
Mol Psychiatry. 2003 Apr;8(4):373-82
12740594
Mol Pharmacol. 2005 Feb;67(2):349-55
15548766
Addict Biol. 2000 Jul 1;5(3):325-9
20575849
Psychopharmacology (Berl). 2005 Apr;179(1):255-61
15619120
J Comp Neurol. 1995 May 8;355(3):455-69
7636025
Biochem Pharmacol. 2008 Jan 1;75(1):218-65
17706608
Addiction. 2007 Apr;102 Suppl 1:49-60
17493053
Eur J Pharmacol. 2004 Sep 19;499(1-2):121-33
15363959
Pharmacol Biochem Behav. 2000 Nov;67(3):405-9
11164066
Neurosci Lett. 1993 Nov 26;163(1):53-7
8295733
J Pharmacol Exp Ther. 2005 Nov;315(2):590-600
16014750
Ann N Y Acad Sci. 1996 Oct 31;801:315-26
8959044
Eur J Pharmacol. 2003 Jul 18;473(1):35-40
12877935
J Neurochem. 2002 Nov;83(3):645-54
12390526
Neuropsychopharmacology. 2007 Mar;32(3):710-8
16794568
Nat Neurosci. 2003 Jul;6(7):743-9
12778052
Neuropsychopharmacology. 2004 May;29(5):921-8
14735132
J Neurosci. 2001 Dec 1;21(23):9471-7
11717381
J Neurosci Methods. 1996 May;66(1):1-11
8794935
Science. 1977 Dec 16;198(4322):1182-3
563103
Nat Neurosci. 2001 Sep;4(9):873-4
11528416
Neuroscience. 2007 Jun 8;146(4):1484-94
17449185
Prog Neurobiol. 2005 Apr;75(6):406-33
15955613
J Neurosci. 2000 Aug 1;20(15):RC89
10899176
Psychopharmacology (Berl). 2006 Jan;183(4):429-38
16292590
Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):422-8
11330336
Brain Res. 1995 Nov 27;700(1-2):99-106
8624733
Psychopharmacology (Berl). 2007 Jan;190(1):21-9
17096086
Drug Alcohol Rev. 2008 May;27(3):229-35
18368603
Neurosci Lett. 2006 Jan 2;391(3):91-5
16153770
Eur J Pharmacol. 2001 Jun 22;422(1-3):87-90
11430918
Dialogues Clin Neurosci. 2007;9(4):389-97
18286799
Psychopharmacology (Berl). 2005 Apr;179(1):262-70
15717208
Drug Alcohol Rev. 2008 May;27(3):309-17
18368613
Trends Pharmacol Sci. 2004 May;25(5):265-72
15120493
Psychopharmacology (Berl). 1998 Oct;139(3):169-84
9784071
Harv Rev Psychiatry. 2005 May-Jun;13(3):141-54
16020027